Bioequivalence Between Generic and Branded Lamotrigine in People With Epilepsy: The EQUIGEN Randomized Clinical Trial

IMPORTANCE: Switching between generic antiepileptic drugs is a highly debated issue that affects both clinical care and overall health care costs. OBJECTIVE: To evaluate the single-dose pharmacokinetic bioequivalence of 3 (1 branded and 2 generic drugs) on-market, immediate-release lamotrigine drug...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:JAMA Neurol
Hauptverfasser: Berg, Michel, Welty, Timothy E., Gidal, Barry E., Diaz, Francisco J., Krebill, Ron, Szaflarski, Jerzy P., Dworetzky, Barbara A., Pollard, John R., Elder, Edmund J., Jiang, Wenlei, Jiang, Xiaohui, Switzer, Regina D., Privitera, Michael D.
Format: Artigo
Sprache:Inglês
Veröffentlicht: American Medical Association 2017
Schlagworte:
Original Investigation
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC5710324/
https://ncbi.nlm.nih.gov/pubmed/28654954
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1001/jamaneurol.2017.0497
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge